do not combine glp-1 receptor agonists with dpp-4 inhibitors guideline The Role of in the Treatment Algorithm of Type 2 Diabetes Mellitus: When to Select, What to Expect DPP-4 and GLP-1 Combination: Safety
Description
AstraZeneca UK Limited sponsored data collection and analysis for this study

A study from the University of Pennsylvania and Cedars-Sinai Medical Center found a 700% increase in use of the drugs for patients without diabetes from 2019 to 2023

Disruption of hepatic adipogenesis is associated with impaired liver regeneration in mice

Assessing the cardiovascular safety of diabetes therapies
[DOI] [PubMed] [Google Scholar] 11.Drucker DJ
W.AyersC.LingeJ.LeinhardO